Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Blocking FcγRIII with anti-CD16 mab (3G8 and GMA161) increases platelets in immune thrombocytopenia: Two pilot studies

View Full Paper
Ask AI
Bookmark
Share

Authors

RKRobert P. KimberlyRNRalph L. NachmanJBJames B. Bussel

Discussion

Loading...

Member takes

Overview

Pilot studies demonstrated rapid platelet responses in chronic ITP using anti-CD16 monoclonal antibodies, highlighting potential therapeutic value.

Key Points

  • Platelet counts rose significantly after anti-CD16 therapy, with 67% of patients showing transient responses.
  • Mean platelet increase was 159 × 10⁹/L for 3G8 and 121 × 10⁹/L for GMA161, peaking by days 4-5.
  • Observational analysis across two pilot studies evaluated immunogenicity, pharmacokinetics, and clinical outcomes.
  • Therapeutic potential is limited by short-lived responses and immune reactions, suggesting further exploration of FcγRIII blockade.

Cite This Study

Kimberly et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e11chttps://doi.org/10.1182/blood-2025-4821
View Full Paper
Ask AI
Bookmark
Share